Designs and manufactures DNA sequencing systems. Develops Single Molecule, Real-Time (SMRT) technology. Now — the numbers.
The biggest line carries real weight, but it doesn’t decide everything on its own.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 2.5× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 16% of them.
Analysts' average target sits 9% below today's price.
Buys outnumber sells, but taken together the trades don’t add up to a strong signal of confidence.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Executive Buying: The trades send no strong signal of confidence.
An investor who bought at the very peak is down 96% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $160.0M a year. A small number, but proof the product has real buyers.
A loss of $546.4M against $160.0M in annual sales.
This stock swings about 2.3 times as much as the market average. Big rallies — and big drops — can both happen fast.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, PACB sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: PACB is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.